Lupus Erythematosus - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 40 pages report, published by Global Markets Direct

Keywords : Lupus Erythematosus Therapeutic Products under Development, Key Players in Lupus Erythematosus Therapeutics, Lupus Erythematosus Pipeline Overview, Lupus Erythematosus Pipeline, Lupus Erythematosus Pipeline Assessment

Report ThumbnailSeptember-2013
Lupus Erythematosus - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lupus Erythematosus - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Erythematosus. Lupus Erythematosus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lupus Erythematosus.
- A review of the Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lupus Erythematosus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Lupus Erythematosus, H2 2013 7
  • Products under Development for Lupus Erythematosus - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Early Clinical Stage Products, H2 2013 10
  • Discovery and Pre-Clinical Stage Products, H2 2013 11
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Combination Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Lupus Erythematosus, H2 2013 7
  • Products under Development for Lupus Erythematosus - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 10
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • AbGenomics International, Inc., H2 2013 13
  • Isotechnika Pharma Inc., H2 2013 14
  • Onyx Pharmaceuticals, Inc., H2 2013 15
  • Farmacija d.o.o. Tuzla, H2 2013 16
  • Five Prime Therapeutics, Inc., H2 2013 17
  • Theraclone Sciences, Inc., H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Combination Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Lupus Erythematosus Therapeutics - Drug Profile Updates 35
  • Lupus Erythematosus Therapeutics - Dormant Products 37
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Lupus Erythematosus Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Lupus Erythematosus 7
  • Lupus Erythematosus Therapeutics under Development by Companies 9
  • Early Clinical Stage Products 10
  • Comparative Analysis 10
  • Discovery and Pre-Clinical Stage Products 11
  • Comparative Analysis 11
  • Lupus Erythematosus Therapeutics - Products under Development by Companies 12
  • Companies Involved in Lupus Erythematosus Therapeutics Development 13
  • AbGenomics International, Inc. 13
  • Isotechnika Pharma Inc. 14
  • Onyx Pharmaceuticals, Inc. 15
  • Farmacija d.o.o. Tuzla 16
  • Five Prime Therapeutics, Inc. 17
  • Theraclone Sciences, Inc. 18
  • Lupus Erythematosus - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Combination Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • Monoclonal Antibodies Targeting Interferon-alfa - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • ONX-0914 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • FPA-008 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • (metenkefalin + tridecactide) - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • ND-2110 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • ND-2158 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • ND-346 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • P-13 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Lupus Erythematosus Therapeutics - Drug Profile Updates 35
  • Lupus Erythematosus Therapeutics - Dormant Products 37
  • Lupus Erythematosus - Product Development Milestones 38
  • Featured News & Press Releases 38
  • Oct 15, 2012: Idera Pharma Likely To Initiate Phase I Study Of Lupus Drug In Fourth Quarter Of 2012 38
  • Appendix 39
  • Methodology 39
  • Coverage 39
  • Secondary Research 39
  • Primary Research 39
  • Expert Panel Validation 39
  • Contact Us 40
  • Disclaimer 40

Please select a license type

Share

Related Products

Global Markets DirectLupus Erythematosus - Pipeline Review, H2 2013Product ThumbnailLupus Erythematosus - Pipeline Review, H2 2013, Industry ReportProduct #: 113349
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved